| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
6:2 FTOH has no therapeutic target; it is an environmental contaminant. It can be degraded by microbial action, significantly affecting the structure of bacterial communities in sediments. In mammals, it may act as a liver and hematological toxicant, with the No Observed Adverse Effect Level (NOAEL) established at 5 mg/kg/day in a 90-day oral gavage study in rats, based on liver and hematology effects.
|
|---|---|
| ln Vitro |
Not applicable; 6:2 FTOH is not a drug and has no direct in vitro biological activity. In vitro, it is used to study the microbial degradation of PFAS and its impact on sediment bacterial ecology. In environmental fate research, it is used to investigate PFAS transformation, and it has been shown to be non-mutagenic in bacterial reverse mutation tests (Ames test) and not clastogenic in human lymphocytes.
|
| ln Vivo |
In vivo, 6:2 FTOH is evaluated in toxicology studies but is not a therapeutic agent. In a 90-day subchronic study, rats were administered 6:2 FTOH by oral gavage (0-250 mg/kg/day). The study NOAEL was 5 mg/kg/day based on hematology and liver effects. It was not a primary skin or eye irritant in rabbits and did not produce dermal sensitization in mice. It is slightly toxic by the oral route (LD50 = 1750 mg/kg in rats).
|
| Enzyme Assay |
Not applicable; 6:2 FTOH is not a standard enzyme inhibitor. For genotoxicity assessment, a bacterial reverse mutation test (Ames test) is performed using Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, and TA98 with and without metabolic activation (S9 mix). 6:2 FTOH was not mutagenic in this assay. A chromosome aberration assay in human lymphocytes also showed it was not clastogenic.
|
| Cell Assay |
Not applicable; 6:2 FTOH is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >500 uM, indicating low to moderate cytotoxicity. For environmental microbiology, bacterial cultures (sediment samples) are incubated with 6:2 FTOH to study microbial community changes by 16S rRNA sequencing.
|
| Animal Protocol |
In vivo toxicity of 6:2 FTOH is evaluated in a 90-day subchronic study in Sprague-Dawley rats. Rats (n=10/sex/group) are administered 6:2 FTOH by oral gavage at doses of 0, 5, 25, 125, and 250 mg/kg/day for 90 days. Clinical observations, body weight, and food consumption are monitored. Hematology, serum chemistry, and histopathology (liver, kidney, spleen, heart, lung) are performed. Mortality was observed at 125 and 250 mg/kg/day. The NOAEL is 5 mg/kg/day. The acute oral LD50 is 1,750 mg/kg. For dermal toxicity, rabbits are treated with 6:2 FTOH (LD50 > 5,000 mg/kg).
|
| ADME/Pharmacokinetics |
6:2 FTOH (MW 364.10) is a lipophilic molecule. Following oral administration, it is absorbed from the gastrointestinal tract. It distributes to the liver and other tissues. The elimination half-life in rodents is expected to be days to weeks, as is common for PFAS compounds. It is not metabolized significantly and is excreted in urine and feces. The compound has low volatility. For research use, it is stored as a liquid at room temperature in a tightly sealed container.
|
| Toxicity/Toxicokinetics |
6:2 FTOH is slightly toxic by the oral route (LD50 = 1,750 mg/kg in rats) and is a skin and eye irritant. In a 90-day subchronic study, the NOAEL was 5 mg/kg/day based on hematology and liver effects. It is not mutagenic in the Ames test and not clastogenic in human lymphocytes. It is not a skin sensitizer. The compound is persistent in the environment and is considered an environmental pollutant. For handling, use PPE (gloves, lab coat, goggles), work in a fume hood, avoid inhalation and skin contact.
|
| References | |
| Additional Infomation |
6:2 Fluorotelomer alcohol (6:2 FTOH; CAS# 647-42-7) is a research-grade short-chain PFAS used in environmental fate studies and microbial degradation research. It is not an FDA-approved drug. It is used as a reference standard for PFAS analysis and in studies of PFAS transformation and toxicology. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C8H5F13O
|
|---|---|
| Molecular Weight |
364.10
|
| Exact Mass |
364.013
|
| CAS # |
647-42-7
|
| PubChem CID |
69537
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
174.1±0.0 °C at 760 mmHg
|
| Flash Point |
91.7±0.0 °C
|
| Vapour Pressure |
0.4±0.7 mmHg at 25°C
|
| Index of Refraction |
1.298
|
| LogP |
4.16
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
395
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C(C(C(F)(F)F)(F)F)(F)F)(C(C(C([H])([H])C([H])([H])O[H])(F)F)(F)F)F
|
| InChi Key |
GRJRKPMIRMSBNK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H5F13O/c9-3(10,1-2-22)4(11,12)5(13,14)6(15,16)7(17,18)8(19,20)21/h22H,1-2H2
|
| Chemical Name |
3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol
|
| Synonyms |
Perfluorohexylethyl alcohol; 6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7465 mL | 13.7325 mL | 27.4650 mL | |
| 5 mM | 0.5493 mL | 2.7465 mL | 5.4930 mL | |
| 10 mM | 0.2746 mL | 1.3732 mL | 2.7465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
